November 29, 2021 | By John Raslavsky | Clinical Research, NAFLD | Blog, Clinical trials, Fatty Liver Disease, liver health
In the medical world, we are always trying to find new ways to treat all kinds of conditions. Non-alcoholic fatty liver disease, or NAFLD, is a condition that we are constantly learning more about, especially in the work of clinical …
October 27, 2021 | By John Raslavsky | Fibroscan, Hepatic Encephalopathy | Blog, Clinical research, Clinical trials, HE
Hepatic encephalopathy (HE) can develop when your liver can no longer remove toxic substances from your blood. The toxins build up and can travel through your body until they eventually reach your brain. This causes mental and physical symptoms of …
September 29, 2021 | By John Raslavsky | Cirrhosis, Fibroscan | Blog, Clinical trials, NAFLD, NASH
Cirrhosis of the liver is a progressive disease, developing slowly over many years. If allowed to continue, the buildup of scar tissue can eventually stop liver function. Because of the gradual decline, liver cirrhosis often goes undetected and unnoticed. You …
July 13, 2021 | By John Raslavsky | Clinical Trials, Liver Disease | Blog, Clinical trials, NAFLD, NASH
The number of U.S. adults with non-alcoholic fatty liver disease (NAFLD) currently sits around 25%. Approximately 2-3% of them will go on to develop non-alcoholic steatohepatitis (NASH). NASH is a more severe form of NAFLD and can lead to fibrosis, …